MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of a drug called Poly-ICLC, also
known as HiltonolTM, in boosting the body's immune system's response to an experimental
vaccine therapy (called the MUC-1 vaccine).